Company profile
Saphetor SA
Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
